Cibus Q4 net loss $277M on $249M goodwill impairment; cash $32.7M

Cibus, Inc.

Net loss $277.2M ($12.59/share) vs $2.8M prior year, driven by $249.4M non-cash goodwill and intangible impairment.
Cash $32.7M at Dec 31, 2023; expects to fund operations into early Q3 2024.
R&D expense $14.2M, SG&A $6.8M, both up significantly from prior year due to merger and headcount.
Business progress: PSR in Canola transferred to 10 customers; HT traits in Rice with Bayer, Nutrien, Nuseed, Interoc.
EU Parliament vote supporting new genomic techniques; opened gene editing production facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cibus, Inc. reported financial results for the quarter ended December 31, 2023.

Period: the quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On March 21, 2024, Cibus, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Cibus, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-012521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.